Jeff Jones
Stock Analyst at Oppenheimer
(1.04)
# 3,598
Out of 4,749 analysts
85
Total ratings
26.03%
Success rate
-11.84%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Initiates: Outperform | $32 | $7.48 | +327.81% | 1 | Jan 30, 2025 | |
| EVH Evolent Health | Maintains: Outperform | $28 → $18 | $10.45 | +72.25% | 4 | Jan 24, 2025 | |
| CLRB Cellectar Biosciences | Downgrades: Perform | n/a | $0.25 | - | 5 | Dec 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $22 → $16 | $3.55 | +350.70% | 7 | Nov 22, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Outperform | $23 | $5.97 | +285.26% | 1 | Nov 18, 2024 | |
| CMMB Chemomab Therapeutics | Reiterates: Outperform | $13 → $11 | $2.04 | +439.22% | 7 | Nov 15, 2024 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $8 → $14 | $5.36 | +161.19% | 3 | Nov 13, 2024 | |
| VTYX Ventyx Biosciences | Reiterates: Outperform | $10 → $9 | $2.01 | +347.76% | 10 | Nov 8, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $52 → $56 | $39.59 | +41.45% | 4 | Sep 27, 2024 | |
| AVBP ArriVent BioPharma | Reiterates: Outperform | $35 → $39 | $28.54 | +36.65% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $87 → $89 | $32.88 | +170.68% | 1 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $10.75 | +318.60% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $9.79 | +798.88% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.84 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $21 | $1.88 | +1,017.02% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.14 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $30 | $30.95 | -3.07% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $0.33 | +35,936.04% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.74 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.42 | +956.34% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $1.51 | +4,866.89% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $2.46 | +44,706.52% | 2 | Nov 17, 2022 |
Alumis
Jan 30, 2025
Initiates: Outperform
Price Target: $32
Current: $7.48
Upside: +327.81%
Evolent Health
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $10.45
Upside: +72.25%
Cellectar Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.25
Upside: -
Perspective Therapeutics
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $3.55
Upside: +350.70%
Y-mAbs Therapeutics
Nov 18, 2024
Initiates: Outperform
Price Target: $23
Current: $5.97
Upside: +285.26%
Chemomab Therapeutics
Nov 15, 2024
Reiterates: Outperform
Price Target: $13 → $11
Current: $2.04
Upside: +439.22%
Corvus Pharmaceuticals
Nov 13, 2024
Reiterates: Outperform
Price Target: $8 → $14
Current: $5.36
Upside: +161.19%
Ventyx Biosciences
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $2.01
Upside: +347.76%
Kymera Therapeutics
Sep 27, 2024
Maintains: Outperform
Price Target: $52 → $56
Current: $39.59
Upside: +41.45%
ArriVent BioPharma
Sep 10, 2024
Reiterates: Outperform
Price Target: $35 → $39
Current: $28.54
Upside: +36.65%
Aug 9, 2024
Reiterates: Outperform
Price Target: $87 → $89
Current: $32.88
Upside: +170.68%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $10.75
Upside: +318.60%
Aug 7, 2024
Maintains: Outperform
Price Target: $80 → $88
Current: $9.79
Upside: +798.88%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.84
Upside: -
May 10, 2024
Maintains: Outperform
Price Target: $16 → $21
Current: $1.88
Upside: +1,017.02%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.14
Upside: -
Feb 29, 2024
Maintains: Neutral
Price Target: $32 → $30
Current: $30.95
Upside: -3.07%
May 25, 2023
Maintains: Outperform
Price Target: $120
Current: $0.33
Upside: +35,936.04%
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $3.74
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.42
Upside: +956.34%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $1.51
Upside: +4,866.89%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $2.46
Upside: +44,706.52%